Plexxikon Wins Tafinlar Patent Dispute Case Against Novartis
The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.
You may also be interested in...
Novartis has announced a major upheaval of its business, which will transform its portfolio and also that of GlaxoSmithKline, and to a lesser extent, that of Lilly. Novartis is to divest its vaccines business to GSK, while GSK will transfer its oncology products to Novartis. The two companies will combine their over-the-counter and consumer healthcare businesses in a joint venture. Separately, Novartis is divesting its animal health business to Lilly.
Following US antitrust clearance, Daiichi Sankyo has completed its acquisition of Plexxikon, successfully sealing a $935 million transaction that will see the formerly private US firm continuing to operate as an independent R&D unit of the Japanese major.
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.